List of Xepi drug patents

Xepi is owned by Ferrer Internacional.

Xepi contains Ozenoxacin.

Xepi has a total of 3 drug patents out of which 0 drug patents have expired.

Xepi was authorised for market use on 11 December, 2017.

Xepi is available in cream;topical dosage forms.

Xepi can be used as treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes.

Drug patent challenges can be filed against Xepi from December, 2021.

The generics of Xepi are possible to be released after 29 January, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6335447 FERRER INTERNACIONAL Quinolonecarboxylic acid derivatives or salts thereof
Nov, 2023

(9 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399014 FERRER INTERNACIONAL Pharmaceutical topical compositions
Dec, 2029

(6 years from now)

US9180200 FERRER INTERNACIONAL Pharmaceutical topical compositions
Jan, 2032

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 11, 2022

Drugs and Companies using OZENOXACIN ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 11 December, 2017

Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes

Dosage: CREAM;TOPICAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in